Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

CERVARIX (PREFILLED SYRINGE) [SIN13374P]

Active ingredients: HPV-16 L1 | HPV-18 L1

View product's general information
Last updated 28 July 2026

Product Info

CERVARIX (PREFILLED SYRINGE)

[SIN13374P]

Product information

Active Ingredient and Strength

HPV-16 L1 - 20 MCG/0.5 ML
HPV-18 L1 - 20 MCG/0.5 ML

Dosage Form

INJECTION, SUSPENSION

Manufacturer and Country

GLAXOSMITHKLINE BIOLOGICALS S.A. - BELGIUM

Registration Number

SIN13374P

Licence Holder

GLAXOSMITHKLINE PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

J07BM02

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

3.1 Therapeutic indications

Cervarix is a vaccine indicated in females from 9 to 25 years of age for the prevention of persistent infection, premalignant cervical lesions and cervical cancer caused by Human Papillomavirus (HPV) Types 16 & 18. See sections 3.4 and 4.1 for important information on the data regarding HPV-16 and/or HPV-18, and other oncogenic HPV types that support this indication – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

The indication is based on the demonstration of efficacy in women aged 15 to 25 years following vaccination with Cervarix and on the immunogenicity of the vaccine in girls and women aged 9 to 25 years.

The use of Cervarix should be in accordance with official recommendations.

Dosing

3.2 Posology and method of administration

The vaccination schedule depends on the age of the subject.

Cervarix Dosage Table 1



The necessity for a booster dose has not been established (see section 4.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Cervarix is for intramuscular injection in the deltoid region. Cervarix should under no circumstances be administered intravascularly or intradermally. No data are available on subcutaneous administration of Cervarix.

Paediatric population: Cervarix is not recommended for use in children below 9 years of age.

Contraindications

3.3 Contraindications

Cervarix should not be administered to subjects with known hypersensitivity to any component of the vaccine (see sections 2 and 5.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Individuals who develop symptoms indicative of hypersensitivity after receiving a dose of Cervarix should not receive further doses of Cervarix.